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Abstract 
 
Recent research in the field of algesiology demonstrated the existence of several types of pain, with 
complex mediation cascades. This fact prompted the use of compounds from other drug families than 
classical analgesics for the treatment of pain. The purpose of this paper is to demonstrate the 
antinociceptive action of sodium valproate in mice. This investigation relies on three nociception models 
that use chemical, thermal, mechanical (pressure) stimuli, and a model of acute inflammation induced by 
carrageenan. The investigations were made using male white Swiss mice, weighing 20-30 grams. 
Valproate administration has been made orally, using geometric progression dose sequences. According 
to the statistical analysis, we obtained values of ED50 for sodium valproate for each nociception model as 
follows: ED50 = 21.773 ± 6.786 mg/kg for the nociception model with Zymosan A, ED50 = 11.807 ± 4.035 
mg/kg, for the hot plate test, ED50 = 19.247 ± 2.207 mg/kg for the Randall-Sellitto test. The action of the 
valproate is explained by the inhibition of pro-inflammatory cytokines like TNF-D IL1E, IL6 and 
prostaglandin mediators like PGE2. The experiments were made according to the European and 
Romanian legislation that concerns working with lab animals. 
 
Rezumat  
 
Cercetările din ultimii ani în domeniul algeziologiei au demonstrat existenĠa mai multor tipuri de durere cu 
mediaĠie complexă ceea ce a atras utilizarea unor compuúi din alte clase decat analgezicele clasice 
pentru tratamentul durerii. Scopul acestei lucrări este de a demonstra acĠiunea antinociceptivă la úoarece 
a valproatului de sodiu. În prezenta lucrare se utilizează trei modele de nocicepĠie care utilizează stimul 
chimic, termic úi presiune úi un model de inflamaĠie acută indusă prin carrageenan. S-a lucrat pe úoareci 
albi masculi, Swiss cu greutăĠi cuprinse între 20-30 g. Administrarea valproatului s-a efectuat pe cale 
orală prin administrarea unor secvenĠe de doze în progresie geometrică. În urma analizei statistice s-au 
obĠinut valori DE50 ale valproatului de sodiu pentru fiecare model de nocicepĠie după cum urmează: DE50 
= 21.773 ± 6.786 mg/kg pentru modelul de nocicepĠie cu Zymosan A, DE50 =11.807 ± 4.035 mg/kg, pentru 
testul Hot plate, DE50 = 19.247 ± 2.207 mg/kg pentru testul Randall-Sellitto. AcĠiunea valproatului se 
explică prin inhibarea citokinelor proinflamatoare de tip TNf - alfa, IL1, beta, IL6 úi a mediatorilor de tip 
PGE2. Experimentele s-au efectuat în accord cu legislaĠia în vigoare în ceea ce priveúte lucrul cu 
animalele de laborator. 
 
Introduction 
 
During the last years, pain has been 
considered not only a symptom, but also a 
disease in itself. The investigations in the 
field of algesiology became extensive and 
brought to attention the existence of several 
types of pain, with a complex mediation.  
Knowing the mediators involved, the 
researchers  sought  new  therapeutic 
possibilities in the treatment of pain.  
Drug from classes other than opioid 
analgesics and non-opioid or non-steroidal 
anti-inflammatories (NSAIDs) have proven 
their analgesic action isolated (tricyclic 
antidepressants,  anticonvulsants),  or  in Chiаac et al.                                                                                                                                        Medicamentul Veterinar / Veterinary Drug 
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combination with other substances. A 
number  of  anticonvulsants  such  as 
carbamazepine and valproic acid are useful 
in the trigeminal neuralgia and neuropathic 
pain [17]. 
In this paper, we are attempting to 
demonstrate the antinociceptive action of 
sodium valproate in mice, using a number of 
different models of nociception involving 
various mediation chains. 
 
1. Materials and Methods 
 
The study was conducted on male Swiss 
mice  (Source  Bucharest  Cantacuzino 
Institute) weighing 20-30 g. The animals 
were placed in plexiglas cages provided with 
water dripper.  
The habitation conditions were set inside 
the  experimental  Pharmacodynamics 
laboratory  in  the  department  of 
Pharmacodynamics and Clinical Pharmacy, 
UMF “Grigore T. Popa” Iasi, in a room with 
controlled temperature and humidity (21°C ± 
2°C) and a cycle of light/dark, 12 / 12 hours 
(07.00 AM/07.00PM).  
The animals received standard food and 
water ad libitum (Biobase Băneasa). The 
tests were carried out beginning with 10.00 
AM and 3 hours before testing access to 
food and water was discontinued. 
All experimental procedures used in this 
study were in close agreement with the 
specific approved norms of the “Grigore T. 
Popa” University of Medicine and the 
international bioethical regulations relating to 
experiments  conducted  on  laboratory 
animals [18].  
For demonstrating the antinociceptive 
action in this study was used:  
x  sodium valproate (Sigma),  
x  Zymosan A (Sigma),  
x  lambda carrageenan (Sigma),  
x  CMC-Na (Sigma) and  
x  saline  (Zentiva). 
The investigations into nociception were 
based on chemical, thermal, and mechanical 
stimuli.  
The test of the abdominal constrictive 
response (methods of Siegmund et al. 1957, 
Koster et al., 1959) induced by Zymosan A, 
meaning the intraperitoneal administration of 
a suspension of Zymosan A at a dose of 40 
mgkgbw
-1. The number of abdominal 
constriction responses for 12 minutes after 
administration of irritants is recorded [13].  
Data interpretation of was quantal, 
characterized by the presence or absence of 
responses calculating the maximal possible 
effect: 
 
% (antinociception) inhibition = (no. non-
responders / total no. of animals) x 100 [11]. 
 
The hot plate test (early method of 
Woolfe and Mac Donald (1944), modified by 
Eddy and Laborit (1953), relies on the 
application of a thermal stimulus (52.5°C), 
during 30 seconds (cutoff time), on the 
plantar faces of the mouse’s paws [4].  
We used the Hot Plate 7280 Ugo Basile 
system, with thermostat for maintaining a 
constant temperature and measurement of 
the exposure time to the thermal stimulus. 
Data interpretation was of the gradual type. 
The antinociceptive effect was appreciated 
using the formula: 
 
% (antinociception) inhibition =  
(Tx-T0)/(Tm+T0) x 100, 
 
Where:  T 0  – the latency of the response measured 
before the administration of the study substance, Tx – 
latency after various time intervals following the 
administration of the substance, Tm – maximal allowed 
time (cut-off time). 
 
The Randall-Selitto test allows the 
assessment of pain and inflammatory 
conditions and consists in the application of a 
mechanical stimulus (pressure) on the 
inflamed paw of the animal (cut-off pressure 
of 250g) [4]. 
The edema is produced by the 
subcutaneous injection into the plantar 
region of 3% saline suspension of 
carrageenan O in mice. For the test was used 
the Ugo Basile analgesy-meter 37215. Data 
interpretation was of the graded type.  Chiаac et al.                                                                                                                                        Medicamentul Veterinar / Veterinary Drug 
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The  antinociceptive  effect  was 
determined by the formula:  
 
% (antinociception) inhibition = (gx+g0)/(gx-g0) 
x 100 
 
where: g0 is the measured response latency before the 
administration of the substance, gx - latency at different 
times in a row after the substance administration, gm - 
the maximum permissible weight (cut-off weight). 
 
The evaluation of the inflammatory 
edema was carried out by measuring the 
volume of  the inflamed paw after 
subcutaneous administration in the plantar 
region of a saline suspension of 3% O-
carrageenan in mice [5, 13].  
For this task, we used the Ugo Basile 
model  7200  plethysmometer.  The 
inflammatory edema calculated the degree of 
inhibition, using the formula: 
 
% inhibition = (M-T) / M x 100, 
 
Where M = value of the degree of inhibition of the 
control group, T = value of the degree of inhibition in 
the treated group. 
 
Statistical analysis of the data 
In order to study the relationships 
between dose and effect, the work protocol 
requires the plotting and the analysis of 
regression lines for both types of effects.  
For measuring the relationship between 
the two variables (the dose-effect), we used 
the Pearson correlation coefficient "R".  
For  assessing  the  antinociceptive 
potential, the Effective Dose 50 (ED50) will be 
calculated, out of the maximum possible 
measured effect. In the statistical analysis for 
all tests, it has been considered that for P 
values < 0.05 there is a statistically 
significant difference between the groups 
compared (ANOVA test). 
 
Results and Discussions 
 
Via the oral administration of subsequent 
doses, ranging from 5.00-40.00 mgkgbw
-1, in 
geometric progression, of a suspension of 
sodium valproate in 0.1% CMC-Na was 
obtained for the abdominal constriction test a 
maximum possible antinociceptive effect 
(MPE) of 80.00%. (Table 1).  
Table 1  
Evaluation of the antinociceptive potential of sodium valproate 
 
Nociception model 
Sodium 
valproate 
Mgkgbw
-1 p.o 
MPE 
(%)  Statistical parameters 
Constrictive abdominal 
response test 
40.00  80.00  ED50 = 21.773 ± 6.786 
Eqn: Y = 1.943 + 2.285*X, R: 0.921 
True Confidence Limits 
(11,338,115.64) log(1.055,2,063) 
20.00  50.32 
10.00  33.33 
5.00  0.00 
Hot plate test  20.0  81.32  ED50 = 11.807 ± 4.035 
Eqn: Y = -29.880 + 74.504*X, R: 0.887 
True Confidence Limits 
(11.685,2.169) log(1.068,0.336) 
ANOVA d.f.(1,2) 
F(calc): 17.379, F(tab): 18.51 
10.00  26.32 
5.00  16.00 
2.50  10.13 
Randall Sellitto test  40.00  65.4  ED50 = 19.247 ± 2.207 
Eqn: Y = -30.126 + 62.386*X R: 0.982 
True Confidence Limits 
(12.044, 42.916) log(1.081,1.633) 
ANOVA d.f.(1,2) 
F(calc): 52.776, F(tab): 18.51 
20.00  56.4 
10.00  34.8 
5.00  10.23 
Inflammatory paw 
edema 
40.00  48.95  ED50 = 45.753 ± 6.964 
Eqn: Y = -4.579 + 32.870*X , R: 0.989 
True Confidence Limits 
(20.097,10.854) log(1.303,1.036) 
F(calc): 43.285, F(tab): 161.4 
20.00  36.45 
10.00  29.16 
   
 
The data in Table 1 allowed plotting the 
regression curves for the determination of 
sodium valproate ED50 for all models of 
nociception studied (Figures 1 to 4). Chiаac et al.                                                                                                                                        Medicamentul Veterinar / Veterinary Drug 
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From the regression analysis (Fig 1) and 
Table 1 it can be is observed that we could 
demonstrate the antinociceptive effect of 
sodium valproate (ED50 = 21.773 ± 6.786 
mgkgbw
-1) in the nociception model with 
Zymosan A. The abdominal constriction 
response test allows for the assessment of 
central and peripheral analgesia.  
 
 
 
Fig. 1 The regression line for determining the 
ED50 for the valproate using the abdominal 
constriction test  
 
 
 
Fig. 2 The regression line for determining the 
ED50 for valproate using the hot-plate test 
 
 
 
Fig. 3 The regression line for determining the 
ED50 for valproate using the Randall Selitto test 
 
 
 
Fig. 4 The regression line for determining the 
ED50 for valproate using the inhibition degree of 
the inflammatory edema 
 
A number of authors have shown that 
intraperitoneal administration of Zymosan in 
mice induces an inflammatory response, 
characterized by the abdominal constriction 
response, the extravasations of plasma, 
leukocyte infiltration and biosynthesis of 
eicosanoids (Doherty cit Pettipher, 1997) [7]. 
Unlike  the  abdominal  constriction 
response produced by the intraperitoneal 
administration  of  acetic  acid,  the 
administration of Zymosan A does not 
produce cell necrosis, and therefore can be 
more relevant to the pathogenesis of 
inflammatory pain. [7, 14]. 
Recently  it  was  revealed  that 
inflammatory agents do not directly stimulate 
the release of primary hyper-nociceptive 
mediators, but that their release is preceded 
by a cascade of cytokines [8]. I t  w a s 
revealed that in mouse, the abdominal 
constriction response to Zymosan and acetic 
acid is mediated by TNF-D, IL1-E and IL8, 
which act simultaneously and synergistically 
(Ribiero cit Cunha 2005) [1]. 
The action mechanism of the valproic 
acid is the inhibition of the enzyme GABA-
transaminase,  responsible  for  the 
degradation of GABA and for the increase in 
the activity  of  the  glutamic  acid 
decarboxylase, acting indirectly on GABA 
[16].  
The literature brings out also other 
possible mechanisms of action that may 
contribute to its antinociceptive effect 
(attenuation of NMDA excitatory action, Chiаac et al.                                                                                                                                        Medicamentul Veterinar / Veterinary Drug 
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blocking of Na channels and of voltage-
dependent calcium channels (type L, C, D, 
N, F, T) and voltage-dependent potassium 
channels [3, 9, 15]. 
Other studies show that valproic acid 
reduces the number of leukocytes and the 
release of myelo-peroxidase in the peritoneal 
exudates in the model of peritonitis with 
carrageenan that produces an inflammatory 
response with involving neutrophils infiltrate, 
plasma exudation, cell migration and release 
of mediators like NO, PGE2, IL 1 E, IL-6, 
TNF-D[10, 16].  
From the regression analysis shown in 
Fig. 3 and from the data in Table 1 we can 
observe an antinociceptive effect of sodium 
valproate (ED50 = 19.247 +/- 2.207) also for 
the inflammatory nociception model induced 
by carrageenan. 
Recent  studies  demonstrate  the 
antinociceptive and anti-inflammatory effect 
of sodium valproate on the paw edema 
induced by carrageenan [16].  
For the inhibition of the inflammatory 
oedema and the dose sequence of taken in 
study we could not identify an ED50 value 
(Table 1). 
The  ED50 value = 11.807 ± 4.035 
mgkgbw
-1 (Table 1, Fig. 2) obtained for the 
hot plate test can be explained by the 
intervention of valproic acid on the Na 
channels from the DRG neurons, including 
the indirect inhibition of sub-threshold slow 
sodium currents and membrane-depolarizing 
rectification [12] and calcium currents [2]. 
Thus, a direct spin cortical inhibition may 
be surmised, because of the inhibitory effect 
on high-frequency action potential firing 
which is directly involved in pain perception 
[6]. To our knowledge, we are the first to 
present such an effect of valproic acid on a 
thermal acute pain model like the hot-plate. 
 
Conclusions 
 
Considering the common mediation for 
the two models of nociception (paw 
inflammatory edema induced by carrageenan 
and abdominal constriction response induced 
by Zymosan A), the close ED50 values and 
the resulting statistical parameters, we 
conclude that the inhibition of nociception in 
inflammatory pain caused by sodium 
valproate may be explained by the inhibition 
of the release of the pro-inflammatory 
cytokines TNF-D type, IL1-E, IL6 and PGE2. 
We have also demonstrated a direct 
anti-nociceptive effect of sodium valproate on 
the pain perception using an acute thermal 
pain model. 
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